An investigation on behalf of investors in Dr.Reddy’s Laboratories Ltd (ADR) (NYSE:RDY) shares over potential wrongdoing at Dr.Reddy’s Laboratories Ltd was announced and NYSE:RDY stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 03/08/2016 --An investigation for shareholders in Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) was announced over potential breaches of fiduciary duties by certain directors at Dr.Reddy's Laboratories Ltd.

Shares of Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) declined from as high as $67.79 per share in October 2015 to as low as $41.34 per share on February 10, 2016.

Investors who purchased shares of Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain Dr.Reddy's Laboratories directors breached their fiduciary duties and caused damage to the company and its shareholders.

On November 6, 2015, Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) issued a statement acknowledging that it has received a warning letter issued by the US FDA dated November 05, 2015 relating to its API manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as Oncology Formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh. Dr.Reddy's Laboratories Ltd said that this action follows the earlier inspections of these sites by the agency in November 2014, January 2015 and February 2015 respectively.

Those who purchased shares of Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com